Podcasts about dsdna

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES 1. Retrospective study of 39 pts w/ MDA5 + DM-ILD Rx w baricitinib. 31 (79.5%) had improvement in Gottron's, heliotrope, dyspnea, HRCT score, ferritin, LDH, steroid dose & 6 mo survival (87% vs. 70%, p = 0.047). https://t.co/RCTbBsCkeV 2. Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with JDM. https://t.co/i2HBycbWY9 3. Myelodysplastic & chr myelomonocytic leukemia pts rarely get lupus. Review of 19 w/ SLE & 5 w/ CLE; these were older (65 yrs), more male (15M/9F), w/ less renal [10%] & articular [36%] Dz w/ less dsDNA [32%]. Thought to be clonal inflammatory, & not autoinflammatory, process. https://t.co/EAvkJm6GQs 4. Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxnhttps://t.co/2qa7O2v6fm 5. No risk of MACE seen w/ initiation of IL-17(R)A inhib. French study of 34 241 ipts Rx IL-17(R)Ai and 381 MACEs. MACE risk was not elevated (OR, 1.25 [95% CI, 0.75-2.08] vs TNF-α inhibitors. https://t.co/WcjgRhr8mj 6. Genetic Risks and Severe Cutaneous Reactions to Allopurinol A matched cohort study shows that HLA-B*58:01 and HLA-A*34:02 are strongly associated with allopurinol-induced severe cutaneous adverse reactions (SCARs), these alleles were absent in more than one-third of those https://t.co/NLpHVhr9Ww 7. Western Australia study of 1854 SLE pts (median 40 yrs old). Interstitial lung disease was seen in in 3.8% of SLE, 26 fold more than controls. Risk factors for ILD included older age, smoking and serositis. SLE-ILD pts had higher mortality rates (MR 52.0, CI 37.0–71.1). 8. 25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/CYwVy7ls7y 9. ACR2025 Non-Renal Lupus Guidelines – from ACR Convergence 2025 10. 900,000 vs 9 It takes about 900,000 minutes to become a board-certified dermatologist. At that point, you might be very skilled and well-informed. It takes less than nine minutes to make your patient feel seen, understood and reassured. If you skip the 9 minutes, you wasted the 900,000  https://t.co/o7BaWjS4HB

#LUPUS #doctorvic #medicinaviral #autoinmune Contacto: dr.vic@sunsetsocial.mxEn este episodio de Medicina viral hablamos de Lupus, o lupus eritematoso sistémico con el Dr. Juan Carlos Arana Ruiz Reumatólogo, Aunque más de cinco millones de personas tienen lupus, muy pocas saben lo que es. El #Lupus es una enfermedad autoinmune que afecta la piel, articulaciones, corazón, pulmones, riñones y cerebro. Produce caída del cabello, cansancio excesivo o pérdida de peso. 90 personas por cada 100 mil habitantes padecen esta enfermedad en #México; de cada 10 casos, entre siete y nueve se presenta en mujeres.El lupus es una enfermedad autoinmune compleja que afecta múltiples órganos y sistemas del cuerpo, incluyendo riñones, corazón, pulmones y cerebro. Esta condición se produce cuando el sistema inmunológico no elimina correctamente las células muertas, lo que provoca inflamación y daño sistémico.Síntomas clave:Entre los síntomas más comunes están el eritema malar (erupción facial), nefritis lúpica (problemas renales) y complicaciones cardíacas y pulmonares. En algunos casos, también afecta el cerebro, causando dificultades cognitivas y cambios de humor.Diagnóstico y tratamiento:El diagnóstico incluye análisis de sangre en busca de anticuerpos anti-dsDNA y marcadores inflamatorios. El tratamiento se enfoca en controlar el sistema inmunológico con corticosteroides, inmunosupresores y, en casos específicos, anticuerpos monoclonales. Hosted on Acast. See acast.com/privacy for more information.

TWiV covers a MacArthur Award for Jason McLellan, 2025 Nobel Prizes in Physiology or Medicine, first treatment for Huntington's Disease, structure of an archael dsDNA virus from head to tail, and discovery of a Legionella phage that explains a determinant of human disease. Hosts: Vincent Racaniello, Alan Dove, and Jolene Ramsey Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Jason McLellan wins MacArthur Award (NPR) 2025 Nobel Prizes Physiology or Medicine (Nobel Prizes) Huntington Disease treatment (BBC) Structure of archaeal tailed virus (Sci Adv) Discovery of Legionella phage (Sci Adv) Microbe of the Month: Legionella (Trends Micro) Letters read on TWiV 1261 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Alan – Specimen of the last female Great Auk finally identified. Jolene – Ribosome studio on IG Vincent – Greater noctule bats prey on and consume passerines in flight Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

With prior Mol Bio Minutes episodes covering DNA form migration and staining considerations for nucleic acid gel electrophoresis, we tie it all together with this great set of overall tips, tricks and resources for the topic. Anyone that's ever run a gel has undoubtedly produced gels with smeared, faint or poorly separated bands. What causes these and how can you avoid them?  Well, Aistė Polikaitytė, Scientist at Thermo Fisher Scientific is here to cover the likely causes and troubleshooting tips to help avoid the most common gel issues. She touches on how much sample to load, the importance of reagent selection, gel preparation, separation conditions, staining, as well as purification and contamination considerations. Helpful resource links mentioned in this episode:Selection guide for electrophoresis dyes and buffersLearn how using precast E-Gel agarose gel can help avoid common issuesA helpful troubleshooting guide for nucleic acid gel electrophoresisView an on-demand webinar covering these topics in more detail Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

You can run the perfect agarose gel to separate your nucleic acid fragments but if you don't stain and image the gel properly, it's all for not. In this second installment of Mol Bio Minutes we take a look at the staining considerations for nucleic acid gel electrophoresis with Paulius Palaima, Product Manager at Thermo Fisher Scientific. He covers the range of stains and staining approaches available while calling out pros, cons and considerations for each. How these recommendations change, depending on your sample, is also covered in this approachable but informative episode. Helpful resource links mentioned in this episode:A helpful DNA stain selection guideRNA stain options and detailsEffects of dyes on gel electrophoresis properties Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Agarose gel electrophoresis is a staple method in almost all biology and biochemistry lab where separation and analysis of nucleic acids is needed. In this Mol Bio Minutes mini episode Augustė Užuotaitė, Scientist III at Thermo Fisher Scientific, covers the basics of electrophoresis with a spotlight on how different forms of DNA migrate differently in agarose gel electrophoresis.In less than 10 quick minutes, you'll learn about the many factors that affect DNA migration rate. Augustė reviews how DNA size, sequence, and conformation all affect migration rate, and she gives some beautifully simple examples to help it all make sense. Helpful resource links mentioned in this episode:Nucleic acid gel electrophoresis – summarized in 5 easy stepsFive important considerations for the nucleic acid gel electrophoresis Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Unfortunately, there simply isn't a one-size-fits-all treatment protocol for patients infected with Lyme disease and/or co-infections. This is why it's critical for physicians treating Lyme disease to invest time with patients, thoroughly understand their medical history, and closely monitor symptoms and treatment response. With that in mind, there are currently two different treatment approaches for Lyme disease. The Infectious Disease Society of America (IDSA) and the International Lyme and Associated Diseases Society (ILADS) have each published their own set of evidence-based treatment guidelines. IDSA guidelines recommend a short course of antibiotics, typically 14 to 30 days. IDSA argues that the Borrelia burgdorferi bacteria do not persist in a patient beyond this timeframe and that lingering symptoms are the result of an ongoing immune response and not an active infection. It also cites scientific evidence claiming treatments beyond 30 days are ineffective, unnecessary, and even dangerous. IDSA physicians will stop treatment after 30 days, even if symptoms remain. They advise an additional 30 days of treatment recommended for patients with Lyme arthritis.  On the contrary, ILADS offers its own scientific data to show that a additional treatment with antibiotics is required to eradicate the bacteria. ILADS recognizes that a month of treatment may be sufficient for patients in the acute stage of Lyme disease, but in cases where the spirochete has disseminated and the disease has advanced, a 30-day treatment regimen is inadequate. ILADS guidelines recommend additional antibiotics until a patient's symptoms have been resolved. Treating Lyme disease in its advanced stage can be complicated based on the complexity of the organism itself, differences in each patient's immune system, the length of time infected, and the possible presence of other co-infections transmitted by the same tick. There are several choices in treating Lyme disease, which include oral, intravenous, and intramuscular antibiotic options. Other options may include sequential antibiotic therapy, higher doses of antibiotics, taking antibiotics for a longer period of time, a combination of antibiotics, retreatment, as well as diagnosing and treating co-infections. Some specific antibiotics used in treating Lyme disease are doxycycline, minocycline, amoxicillin, cefuroxime, azithromycin, and clarithromycin. Other tests include measures of blood counts, chemistries, liver function tests, ANA, dsDNA, RF, TSH, free T3, free T4, ESR may be helpful at ruling out other conditions.  Referral to specialist might help to rule out other conditions.  I find shared decision with my patient helpful. I also find follow-up helpful to assess my patient's response to treatment to rule out other conditions. There are additional protocols that may also aid in treating Lyme disease, such as avoiding alcohol, simple and processed sugars, exercising as tolerated, counseling for a Jarisch-Herxheimer reaction, managing symptoms, monitoring and reducing the risk of an adverse event, and reducing stress. However, there is a chance of side effects such as Clostridium difficile-associated diarrhea (CDAD). Probiotic have been prescribed with the hope of reducing the risk of developing CDAD.   

What is a common-sense approach to testing for Tick-borne infection. I focus on the most common infections that I see a Lyme disease infection. I order a Lyme disease test as well as test for infections like Ehrlichia, Anaplasmosis, and Babesia. I don't typically order Mycoplasma or Chlamydia unless there is evidence that there's active infection.  I order an ELISA test, which is also called Lyme titer.  I also order a western blot and IgG and IgM test. These are test where you need two out of three bands IgM bands. You need five out of 10 IgG bands to be called positive by the CDC criteria. These are bands that were identified and in 1994 at a consensus meeting in Dearborn Michigan.  These markers are protein that have been identified in Lyme disease infections.  For example, the 41 kDa band represents a protein contained in the tail of a spirochete. I have not been ordering a C6 peptide or VlsE protein tests for Lyme disease as they are not as reliable as I would like.  None of these tests for Lyme disease are all that sensitive in my experience.  I have often had to use clinical judgement to diagnose and treat Lyme disease. I also order IgG and IgM tests for co-infections with Babesia, Bartonella, Anaplasmosis, and Ehrlichia. I have not found PCR tests for these co-infections as helpful as I would like. I have found a blood smear for Babesia not helpful if a patient has been sick more than 2 weeks.   Some doctors have assumed Bartonella tests have been positive due to exposure to fecal matter from mites living on cats. I can't be sure the cause of positive tests for Bartonella in patients with Lyme disease.  I don't typically ordered labs for infections such as tularemia or Brucellosis despite concerns by some of my colleagues. I have found treatment for Lyme disease would take care of these infections if they were present. I typically do not sent bloods to a specialty lab if someone's on a budget. I also do not send bloods to these labs if I am going to treat clinically.   I also order extensive testing to rule other illnesses like a CBC, comprehensive metabolic profile, ANA, RA, thyroid, sed rate, vitamin B12 and D.    I may order a free T4 and free T3 if I am considering a thyroid condition.  I have found ANA frustrating as most of the ANA tests are false positive. A positive dsDNA supports the diagnosis of lupus. My patients don't typically have three other conditions that would support the diagnosis of Lupus. I refer my patients to see a rheumatologist if there is a need to rule out lupus. I typical order blood test for a tick-borne illness four weeks or 4 to 6 weeks after onset of their illness to increase the chances that I might get a positive test.  I have had to use clinical judgement to treat a tick-borne infection if my patient is sick for less than 4 weeks or if I suspect a false negative test,

CardioNerds join Dr. Inbar Raber and Dr. Susan Mcilvaine from the Beth Israel Deaconess Medical Center for a Fenway game. They discuss the following case: A 72-year-old man presents with two weeks of progressive dyspnea, orthopnea, nausea, vomiting, diarrhea, and right upper quadrant pain. He has a history of essential thrombocytosis, Barrett's esophagus, basal cell skin cancer, and hypertension treated with hydralazine. He is found to have bilateral pleural effusions and a pericardial effusion. He undergoes a work-up, including pericardial cytology, which is negative, and blood tests reveal a positive ANA and positive anti-histone antibody. He is diagnosed with drug-induced lupus due to hydralazine and starts treatment with intravenous steroids, resulting in an improvement in his symptoms. Expert commentary is provided by UT Southwestern internal medicine residency program director Dr. Salahuddin (“Dino”) Kazi. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media Pearls - A Drug's Adverse Effect Unleashes the Wolf The differential diagnosis for pericardial effusion includes metabolic, malignant, medication-induced, traumatic, rheumatologic, and infectious etiologies. While pericardial cytology can aid in securing a diagnosis of cancer in patients with malignant pericardial effusions, the sensitivity of the test is limited at around 50%.  Common symptoms of drug-induced lupus include fever, arthralgias, myalgias, rash, and/or serositis. Anti-histone antibodies are typically present in drug-induced lupus, while anti-dsDNA antibodies are typically absent (unlike in systemic lupus erythematosus, SLE). Hydralazine-induced lupus has a prevalence of 5-10%, with a higher risk for patients on higher doses or longer durations of drug exposure. Onset is usually months to years after drug initiation. Show Notes - A Drug's Adverse Effect Unleashes the Wolf There is a broad differential diagnosis for pericardial effusion which includes metabolic, malignant, medication-induced, traumatic, rheumatologic, and infectious etiologies. Metabolic etiologies include renal failure and thyroid disease. Certain malignancies are more likely to cause pericardial effusions, including lung cancer, lymphoma, breast cancer, sarcoma, and melanoma. Radiation therapy to treat chest malignancies can also result in a pericardial effusion. Medications can cause pericardial effusion, including immune checkpoint inhibitors, which can cause myocarditis or pericarditis, and medications associated with drug-induced lupus, such as procainamide, hydralazine, phenytoin, minoxidil, or isoniazid. Trauma can cause pericardial effusions, including blunt chest trauma, cardiac surgery, or cardiac catheterization. Rheumatologic etiologies include lupus, rheumatoid arthritis, systemic sclerosis, sarcoid, and vasculitis. Many different types of infections can cause pericardial effusions, including viruses (e.g., coxsackievirus, echovirus, adenovirus, human immunodeficiency virus, and influenza), bacteria (TB, staphylococcus, streptococcus, and pneumococcus), and fungi. Other must-not-miss etiologies include emergencies like type A aortic dissection and myocardial infarction. In a retrospective study of all patients who presented with a hemodynamically significant pericardial effusion and underwent pericardiocentesis, 33% of patients were found to have an underlying malignancy(Ben-Horin et al). Bloody effusion and frank tamponade were significantly more common among patients with malignant effusion, but the overlap was significant, and no epidemiologic or clinical parameter was found useful to differentiate between cancerous and noncancerous effus...

Dr. Anna Wolska speaks to Dr. Michael Belmont and Devyn Zaminski to discuss the importance of dual dsDNA testing in order to full understand disease activity. In this study, they made the observation that there is a large amount of discordance in anti-dsDNA antibodies assays. Misinterpretation or errors in anti- dsDNA antibody testing could have negative implications on long term outcomes in people living with SLE.   Read the related paper - https://doi.org/10.1136/lupus-2023-001012

4.11 Antibody Review Rheumatology review for the USMLE Step 1 Exam. ANA Principles ANA (Anti-Nuclear Antibody): Non-specific antibody. Reacts against nuclear antigens, including proteins, DNA, RNA, and nucleic acid-protein complexes. Includes a group of antibodies such as anti-dsDNA, anti-histone, SSA/Ro, SSB/La, Scl-70, anti-aminoacyl-tRNA synthetase (Jo-1). Found in 20-30% of the general public without connective tissue disorder symptoms. ANA+ individuals may or may not have a rheumatologic disorder. Further workup is needed in ANA+ cases to determine the specific disorder. Antibodies by Disease Process Systemic Lupus Erythematosus (SLE) Anti-dsDNA antibody. Anti-Smith antibody. Drug-Induced Lupus Anti-histone antibody. Diffuse vs. Limited Scleroderma Diffuse: Anti-Scl-70 (anti-topoisomerase I). Limited: Anti-centromere (often called CREST syndrome, with CREST standing for centromere). Sjogren's Syndrome Anti-SSA (Ro). Anti-SSB (La), which usually occurs in the presence of SSA. SSA is considered the Sjogren-specific antibody, leading to the presence of SSB. Rheumatoid Arthritis (RA) Anti-CCP (Cyclic Citrullinated Peptide). RF (Rheumatoid Factor) is non-specific. Thanks for listening!

Find Monica:  Website: https://monicasdeepdives.com Twitter: https://twitter.com/monicaperezshow Rokfin: https://rokfin.com/deepdives Rumble: https://rumble.com/user/monicaperezshow YouTube: https://www.youtube.com/c/MonicaPerez  Shownotes: 1) EMA Quality Report - Rapporteurs-Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine- BioNTec.doc (live.com) 2) SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1111/apm.13294 3) Biodistribution of mRNA COVID-19 vaccines in human breast milk https://www.thelancet.com/action/showPdf?pii=S2352-3964%2823%2900366-3 4) FDA - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum https://www.fda.gov/media/144416/download 5) EMA Comirnaty Assessment Report - https://www.ema.europa.eu/en/documents/assessment- report/comirnaty-epar-public-assessment-report_en.pdf 6) Three decades of messenger RNA vaccine development - ScienceDirect 7) Frontiers | Are There Hidden Genes in DNA/RNA Vaccines? (frontiersin.org) 8) Effect of mRNA Vaccine Manufacturing Processes on Efficacy and Safety Still an Open Question | The BMJ 9) Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line (nih.gov) 10) dsDNA variance in Pfizer Docs - by Anandamide (substack.com) 11) COVID-19 primary series and booster vaccination and immune imprinting https://www.medrxiv.org/content/10.1101/2022.10.31.22281756v1.full.pdf 12) Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061025 13) A SYSTEMATIC REVIEW OF AUTOPSY FINDINGS IN DEATHS AFTER COVID-19 VACCINATION: https://zenodo.org/record/8120771 14) Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine (Cleveland Clinic Study): https://academic.oup.com/ofid/article/10/6/ofad209/7131292?login=false 15) Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents: https://pubmed.ncbi.nlm.nih.gov/36006288/ 16) Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria | Kevin McKernan: https://rumble.com/v2c785k-march-8-2023.html?mref=umbzp&mc=dprv6 17) BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis: https://onlinelibrary.wiley.com/doi/10.1111/eci.13759 18) SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents: https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253 19) Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults: https://www.sciencedirect.com/science/article/pii/S0264410X22010283 20) N1 methylpseudouridine is incorporated with higher fdelity than pseudouridine in synthetic RNAs (demonstrates high error rates) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335462/pdf/41598_2022_Article_17249.pdf 22) LNP packaging of dsDNA: https://anandamide.substack.com/p/lnp-packaging-of-dsdna 23) IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/ 24) COVID-19 vaccine-associated mortality in the Southern Hemisphere: https://correlation- canada.org/covid-19-vaccine-associated-mortality-in-the-southern-hemisphere/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Find Monica:  Website: https://monicasdeepdives.com Twitter: https://twitter.com/monicaperezshow Rokfin: https://rokfin.com/deepdives Rumble: https://rumble.com/user/monicaperezshow YouTube: https://www.youtube.com/c/MonicaPerez  Shownotes: 1) EMA Quality Report - Rapporteurs-Rolling-Review-Report-Quality-COVID-19-mRNA-Vaccine- BioNTec.doc (live.com) 2) SARS-CoV-2 spike mRNA vaccine sequences circulate in blood up to 28 days after COVID-19 vaccination: https://onlinelibrary.wiley.com/doi/10.1111/apm.13294 3) Biodistribution of mRNA COVID-19 vaccines in human breast milk https://www.thelancet.com/action/showPdf?pii=S2352-3964%2823%2900366-3 4) FDA - Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum https://www.fda.gov/media/144416/download 5) EMA Comirnaty Assessment Report - https://www.ema.europa.eu/en/documents/assessment- report/comirnaty-epar-public-assessment-report_en.pdf 6) Three decades of messenger RNA vaccine development - ScienceDirect 7) Frontiers | Are There Hidden Genes in DNA/RNA Vaccines? (frontiersin.org) 8) Effect of mRNA Vaccine Manufacturing Processes on Efficacy and Safety Still an Open Question | The BMJ 9) Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line (nih.gov) 10) dsDNA variance in Pfizer Docs - by Anandamide (substack.com) 11) COVID-19 primary series and booster vaccination and immune imprinting https://www.medrxiv.org/content/10.1101/2022.10.31.22281756v1.full.pdf 12) Circulating Spike Protein Detected in Post–COVID-19 mRNA Vaccine Myocarditis: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.061025 13) A SYSTEMATIC REVIEW OF AUTOPSY FINDINGS IN DEATHS AFTER COVID-19 VACCINATION: https://zenodo.org/record/8120771 14) Effectiveness of the Coronavirus Disease 2019 Bivalent Vaccine (Cleveland Clinic Study): https://academic.oup.com/ofid/article/10/6/ofad209/7131292?login=false 15) Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents: https://pubmed.ncbi.nlm.nih.gov/36006288/ 16) Deep sequencing of the Moderna and Pfizer bivalent vaccines identifies contamination of expression vectors designed for plasmid amplification in bacteria | Kevin McKernan: https://rumble.com/v2c785k-march-8-2023.html?mref=umbzp&mc=dprv6 17) BNT162b2 Vaccine-Associated Myo/Pericarditis in Adolescents: A Stratified Risk-Benefit Analysis: https://onlinelibrary.wiley.com/doi/10.1111/eci.13759 18) SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents: https://jamanetwork.com/journals/jamacardiology/fullarticle/2791253 19) Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults: https://www.sciencedirect.com/science/article/pii/S0264410X22010283 20) N1 methylpseudouridine is incorporated with higher fdelity than pseudouridine in synthetic RNAs (demonstrates high error rates) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335462/pdf/41598_2022_Article_17249.pdf 22) LNP packaging of dsDNA: https://anandamide.substack.com/p/lnp-packaging-of-dsdna 23) IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/ 24) COVID-19 vaccine-associated mortality in the Southern Hemisphere: https://correlation- canada.org/covid-19-vaccine-associated-mortality-in-the-southern-hemisphere/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Dan Wilson returns to TWiV to debunk vaccine misinformation by RFK Jr. during his recent appearance on the Joe Rogan Experience. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler, and Brianne Barker Guest: Dan Wilson Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server Joe Rogan's worst misinformation yet, with RFK Jr. (YouTube) Every first vaccine has been tested in placebo-controlled trials before going to market. Polio Measles HPV COVID-19 HepB Haemophilus influenzae B Pertussis Diphtheria Tetanus Pneumococcal Mumps Meningococcal Chickenpox HepA KiGGS Study results on atopic diseases after vaccination (Vaccine) Vaccine history by year (CHOP) Financing vaccines in the 21st Century (Nat Acad Press) DALY rates from non-communicable diseases (Our World in Data) Science loses one to creationism (WaPo) Children's Health Defense (Wikipedia) COVID-19 vaccines saved 3 million US lives (CIDRAP) Beyond the Noise with Paul Offit (YouTube) Letters read on TWiV 1026 Timestamps by Jolene. Thanks! Weekly Picks Dickson – Jazz G.O.A.T.S – Louis Armstrong, Duke Ellington, Ella Fitzgerald Brianne – Defining the Anthropocene? Kathy – How to use your thermostat on A/C Rich – Star Trek: Strange New Worlds Vincent – Step Aside, Joe Biden Listener Picks Kim – Virus found in a boreal lake links ssDNA and dsDNA viruses and Structure of ssDNA bacteriophage ΦCjT23 provides insight into early virus evolution Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

In this episode our host, Dr Raquel Faria, is joined by Professors Ricard Cervera and Zahir Amoura who will be providing expert insights from the key lupus research in 2022.  For the full written report '2022 Year in Review' please refer to our online library: https://www.lupus-academy.org/library/congress-reports Disclaimer: ‘During Lupus Academy podcast episodes, participants may refer to off label use of medicines for patients with lupus. Lupus Academy does not make any recommendations about using a medicine outside the terms of its approved licence for use.' References for this episode: Bruce IN, Furie RA, Morand EF, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022;81(7):962-969. Dörner T, van Vollenhoven RF, Doria A, et al. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. Arthritis Res Ther. 2022;24(1):112. Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100-107. Furie RA, Hough DR, Gaudy A, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022;9(1). Furie RA, van Vollenhoven RF, Kalunian K, Navarra S, Romero-Diaz J, Werth VP, Huang X, Clark G, Carroll H, Meyers A, Musselli C, Barbey C, Franchimont N; LILAC Trial Investigators. Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus. N Engl J Med. 2022 Sep 8;387(10):894-904. Ginzler E, Guedes Barbosa LS, D'Cruz D, et al. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2022;74(1):112-123. Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496-506. Sun L, Shen Q, Gong Y, Li Y, Lv Q, Liu H, Zhao F, Yu H, Qiu L, Li X, He X, Chen Y, Xu Z, Xu H. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: A self-controlled before-after trial. Lupus. 2022 Jul;31(8):998-1006. van Vollenhoven RF, Hahn BH, Tsokos GC, et al. Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. J Rheumatol. 2022;49(4):380-387.

Die Themen in den Wissensnachrichten: +++ Archäologie-Team interpretiert Linien und Pünktchen in Höhlenmalereien als eine Art Jäger-Kalender +++ Neue Variante der CRISPR-Cas-Genschere könnte gegen Krebszellen helfen +++ Kartoffelförmige Steine flitschen höher +++ **********Weiterführende Quellen zu dieser Folge:An Upper Palaeolithic Proto-writing System and Phenological Calendar, Cambridge Archaeological Journal, 05.01.2023Cas12a2 elicits abortive infection via RNA-triggered destruction of dsDNA. Nature, 04.1.2023The role of body shape and mass in skimming on water, Proceedings of the Royal Society A, 04.01.2023Decoupling the skull and skeleton in a Cretaceous bird with unique appendicular morphologies, Nature Eology and Evolution, 02.01.2023I Love It, I'll Never Use It: Exploring Factors of Product Attachment and Their Effects on Sustainable Product Usage Behaviors, International Journal of Design, Dezember 2022**********Ihr könnt uns auch auf diesen Kanälen folgen: Tiktok und Instagram.**********Weitere Wissensnachrichten zum Nachlesen: https://www.deutschlandfunknova.de/nachrichten

Lumpy skin disease (LSD) is a WOAH notifiable transboundary cattle disease caused by lumpy skin disease virus (LSDV), a dsDNA virus member of the Capripoxvirus genus, belonging to the Poxviridae family. LSD primarily affects cattle, causing fever, enlarged lymph nodes, lesions of the oral mucous membranes, of the respiratory, and digestive tract, abortions and a reduction in milk production. Considering the important economic impact on livestock, innovative and effective tools to detect the virus in fields would be of the greatest interest to speed up the diagnosis. Given its feasibility in field conditions and its easiness to use, lateral flow immunoassay (LFIA) could fulfil this goal. This study aimed at developing LFIA using monoclonal antibodies (mAb) produced against p32 LSDV structural protein and evaluating the preliminary specificity and sensitivity.

Lumpy skin disease (LSD) is a WOAH notifiable transboundary cattle disease caused by lumpy skin disease virus (LSDV), a dsDNA virus member of the Capripoxvirus genus, belonging to the Poxviridae family. LSD primarily affects cattle, causing fever, enlarged lymph nodes, lesions of the oral mucous membranes, of the respiratory, and digestive tract, abortions and a reduction in milk production. Considering the important economic impact on livestock, innovative and effective tools to detect the virus in fields would be of the greatest interest to speed up the diagnosis. Given its feasibility in field conditions and its easiness to use, lateral flow immunoassay (LFIA) could fulfil this goal. This study aimed at developing LFIA using monoclonal antibodies (mAb) produced against p32 LSDV structural protein and evaluating the preliminary specificity and sensitivity.

Prot —> mRNA —> cDNA —> dsDNA. (Step 2 via reverse transcriptase and step 3 via DNA Polymerase). Now the dsDNA is injected into a virus which infects bacteria to make lots of the DNA.